Potassium Citrate–Lisdexamfetamine Pharmacologic Interaction
Potassium citrate is an urinary alkalinizing agent. [1] Urinary alkalinizing agents can increase blood levels of amphetamine from lisdexamfetamine (Vyvanse). [1] Because of this interaction, VYVANSE dosage adjustment may be required when urinary alkalinizing agents are used. [1]
Mechanism of Interaction
Lisdexamfetamine (Vyvanse) effects depend on amphetamine blood levels. [1] Urinary pH alterations change urinary excretion of amphetamine. [1] Urinary alkalinizing agents increase amphetamine blood levels. [1]
Clinical Implications
Increased amphetamine exposure can increase stimulant-related adverse effects. [1] Potential consequences include increased blood pressure and heart rate. [1]
Practical Medication-Management Considerations
Concurrent use is not described as contraindicated. [1] Dosage of VYVANSE should be adjusted according to labeling guidance when urinary alkalinizing agents are used. [1]
Monitoring When Used Together
Monitoring should focus on symptoms consistent with increased amphetamine exposure and cardiovascular effects. [1]
Safety Notes for Potassium Citrate
Potassium citrate treatment raises urinary pH and is intended to maintain an alkaline urine. [1] Potassium citrate can increase serum potassium risk in patients predisposed to hyperkalemia. [2]